John Buse, MD, PhD discusses the expanding role of GLP-1 receptor agonists in treatment of cardiovascular conditions.
John B. Buse, MD, PhD
Advertisement
Articles by John B. Buse, MD, PhD
Advertisement
Latest Updated Articles
Semaglutide and Cardiovascular Risk Reduction: What the Latest Data Tell UsPublished: March 30th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
3
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5